APA (7th ed.) Citation

Olszewska-Szopa, M., Ożańska, A., Ożański, T., Rybka, J., & Wróbel, T. (2024). The comparison of safety and cost between reference drug of rituximab and its biosimilar Riximyo in lymphoproliferative disorders and other hematological diseases. Single center experience. Leukemia & Lymphoma, 65(1), 55. https://doi.org/10.1080/10428194.2023.2271595

Chicago Style (17th ed.) Citation

Olszewska-Szopa, Magdalena, Agnieszka Ożańska, Tomasz Ożański, Justyna Rybka, and Tomasz Wróbel. "The Comparison of Safety and Cost Between Reference Drug of Rituximab and Its Biosimilar Riximyo in Lymphoproliferative Disorders and Other Hematological Diseases. Single Center Experience." Leukemia & Lymphoma 65, no. 1 (2024): 55. https://doi.org/10.1080/10428194.2023.2271595.

MLA (9th ed.) Citation

Olszewska-Szopa, Magdalena, et al. "The Comparison of Safety and Cost Between Reference Drug of Rituximab and Its Biosimilar Riximyo in Lymphoproliferative Disorders and Other Hematological Diseases. Single Center Experience." Leukemia & Lymphoma, vol. 65, no. 1, 2024, p. 55, https://doi.org/10.1080/10428194.2023.2271595.